Literature DB >> 11324985

Review: uveitis and immunosuppressive drugs.

P Kulkarni1.   

Abstract

Uveitis, inflammation of the eye, is a common occurring disease resulting from a wide variety of traumatic and immunogenic insults and, in most cases, can be treated successfully by corticosteroids. However, corticosteroids have severe side effects. Alternative therapy is using nonsteroidal anti-inflammatory agents like indomethecin, diclofenac and flurbiprofen. The uveitic cases are prominent in the third world countries, and many of the patients are not responsive or become refractory to steroidal or nonsteroidal therapy. Therefore, there is another class of compounds "immunosuppressive drugs" found to be successful in treating uveitis. These include cyclosporin A, tacrolimus, and sirolimus. However, being immunosuppressive they also have side effects. Therefore, the effective therapy with lower side effects is the treatment with combination of these drugs in lower dosages. Cyclosporin A plus sirolimus or tacrolimus in threshold doses alleviate signs of uveitis with lower incidence of side effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11324985     DOI: 10.1089/10807680151125537

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  9 in total

1.  Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Control Release       Date:  2012-01-27       Impact factor: 9.776

Review 2.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 3.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis.

Authors:  Xiaoguang Dong; Weiyun Shi; Gongqiang Yuan; Lixin Xie; Shenguo Wang; Ping Lin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-15       Impact factor: 3.117

5.  LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells.

Authors:  Matthew A Cunningham; Bobbie Ann Austin; Zhuqing Li; Baoying Liu; Steven Yeh; Chi-Chao Chan; Eddy Anglade; Poonam Velagaleti; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

6.  Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation.

Authors:  Olga A Kost; Olga V Beznos; Nina G Davydova; Devika S Manickam; Irina I Nikolskaya; Anna E Guller; Petr V Binevski; Natalia B Chesnokova; Anatoly B Shekhter; Natalia L Klyachko; Alexander V Kabanov
Journal:  Oxid Med Cell Longev       Date:  2015-12-01       Impact factor: 6.543

7.  Determination of Genes Related to Uveitis by Utilization of the Random Walk with Restart Algorithm on a Protein-Protein Interaction Network.

Authors:  Shiheng Lu; Yan Yan; Zhen Li; Lei Chen; Jing Yang; Yuhang Zhang; Shaopeng Wang; Lin Liu
Journal:  Int J Mol Sci       Date:  2017-05-13       Impact factor: 5.923

8.  Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit.

Authors:  Mohammad Abbaszadeh Hasiri; Effat Baghaei Moghaddam; Mohammad Reza Khalili; Amin Hossein Amini; Masoomeh Eghtedari; Mohammad Azizzadeh; Hooman Razmi
Journal:  Vet Res Forum       Date:  2018-12-15       Impact factor: 1.054

Review 9.  Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review.

Authors:  Alireza Ebrahimi; Hanie Ahmadi; Zahra Pourfraidon Ghasrodashti; Nader Tanide; Reza Shahriarirad; Amirhossein Erfani; Keivan Ranjbar; Soheil Ashkani-Esfahani
Journal:  Bosn J Basic Med Sci       Date:  2021-12-01       Impact factor: 3.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.